Vincenzo Ingangi

536 total citations
15 papers, 323 citations indexed

About

Vincenzo Ingangi is a scholar working on Molecular Biology, Cancer Research and Immunology and Allergy. According to data from OpenAlex, Vincenzo Ingangi has authored 15 papers receiving a total of 323 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 7 papers in Cancer Research and 5 papers in Immunology and Allergy. Recurrent topics in Vincenzo Ingangi's work include Protease and Inhibitor Mechanisms (7 papers), S100 Proteins and Annexins (6 papers) and Cell Adhesion Molecules Research (5 papers). Vincenzo Ingangi is often cited by papers focused on Protease and Inhibitor Mechanisms (7 papers), S100 Proteins and Annexins (6 papers) and Cell Adhesion Molecules Research (5 papers). Vincenzo Ingangi collaborates with scholars based in Italy, France and United States. Vincenzo Ingangi's co-authors include Maria Vincenza Carriero, Michele Minopoli, Maria Letizia Motti, Concetta Ragone, Ilaria Marigo, Laura Pinton, Elena Masetto, Elisa Peranzoni, Ali Munaim Yousif and Paolo Grieco and has published in prestigious journals such as PLoS ONE, Scientific Reports and Journal of Controlled Release.

In The Last Decade

Vincenzo Ingangi

15 papers receiving 320 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vincenzo Ingangi Italy 12 142 120 102 86 33 15 323
Valentina Poltavets Australia 4 148 1.0× 202 1.7× 87 0.9× 86 1.0× 29 0.9× 6 375
Xiaoli Hui China 10 217 1.5× 187 1.6× 81 0.8× 71 0.8× 29 0.9× 16 479
Billy Samuel Hill Italy 6 182 1.3× 177 1.5× 63 0.6× 87 1.0× 15 0.5× 7 341
Yaxun Wu China 13 257 1.8× 103 0.9× 58 0.6× 118 1.4× 24 0.7× 23 398
Vitor H. Almeida Brazil 11 235 1.7× 144 1.2× 159 1.6× 97 1.1× 56 1.7× 20 463
Elias Sundquist Finland 9 124 0.9× 136 1.1× 55 0.5× 105 1.2× 34 1.0× 12 328
Siri Juell Norway 12 148 1.0× 119 1.0× 166 1.6× 43 0.5× 15 0.5× 16 373
Steven King United States 3 288 2.0× 116 1.0× 53 0.5× 130 1.5× 87 2.6× 8 469
Jane Cullis United States 5 141 1.0× 147 1.2× 93 0.9× 45 0.5× 20 0.6× 8 309
Scott Chartrand United States 5 236 1.7× 93 0.8× 46 0.5× 126 1.5× 22 0.7× 5 368

Countries citing papers authored by Vincenzo Ingangi

Since Specialization
Citations

This map shows the geographic impact of Vincenzo Ingangi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincenzo Ingangi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincenzo Ingangi more than expected).

Fields of papers citing papers by Vincenzo Ingangi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vincenzo Ingangi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincenzo Ingangi. The network helps show where Vincenzo Ingangi may publish in the future.

Co-authorship network of co-authors of Vincenzo Ingangi

This figure shows the co-authorship network connecting the top 25 collaborators of Vincenzo Ingangi. A scholar is included among the top collaborators of Vincenzo Ingangi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vincenzo Ingangi. Vincenzo Ingangi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Ingangi, Vincenzo, Annarosaria De Chiara, Michele Gallo, et al.. (2024). Emerging Treatments Targeting the Tumor Microenvironment for Advanced Chondrosarcoma. Cells. 13(11). 977–977. 7 indexed citations
2.
Grigoletto, Antonella, et al.. (2023). Improving the Therapeutic Potential of G-CSF through Compact Circular PEGylation Based on Orthogonal Conjugations. Biomacromolecules. 24(9). 4229–4239. 4 indexed citations
3.
Pinton, Laura, Elena Masetto, Vincenzo Ingangi, et al.. (2020). Targeting of immunosuppressive myeloid cells from glioblastoma patients by modulation of size and surface charge of lipid nanocapsules. Journal of Nanobiotechnology. 18(1). 31–31. 32 indexed citations
4.
Grigoletto, Antonella, Ilaria Marigo, Vincenzo Ingangi, et al.. (2020). Poly(L-glutamic acid)-co-poly(ethylene glycol) block copolymers for protein conjugation. Journal of Controlled Release. 324. 228–237. 7 indexed citations
5.
Peranzoni, Elisa, Vincenzo Ingangi, Elena Masetto, Laura Pinton, & Ilaria Marigo. (2020). Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade. Frontiers in Immunology. 11. 1590–1590. 53 indexed citations
6.
Ingangi, Vincenzo, Michele Minopoli, Concetta Ragone, Maria Letizia Motti, & Maria Vincenza Carriero. (2019). Role of Microenvironment on the Fate of Disseminating Cancer Stem Cells. Frontiers in Oncology. 9. 82–82. 53 indexed citations
7.
Minopoli, Michele, Andrea Polo, Concetta Ragone, et al.. (2019). Structure-function relationship of an Urokinase Receptor-derived peptide which inhibits the Formyl Peptide Receptor type 1 activity. Scientific Reports. 9(1). 15 indexed citations
8.
Ragone, Concetta, Michele Minopoli, Vincenzo Ingangi, et al.. (2017). Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells. Journal of Experimental & Clinical Cancer Research. 36(1). 180–180. 16 indexed citations
9.
Yousif, Ali Munaim, Vincenzo Ingangi, Francesco Merlino, et al.. (2017). Urokinase receptor derived peptides as potent inhibitors of the formyl peptide receptor type 1-triggered cell migration. European Journal of Medicinal Chemistry. 143. 348–360. 21 indexed citations
10.
Carriero, Maria Vincenza, Katia Bifulco, Vincenzo Ingangi, et al.. (2017). Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas. Scientific Reports. 7(1). 1312–1312. 24 indexed citations
11.
Ingangi, Vincenzo, et al.. (2016). A Macroscopic Mathematical Model for Cell Migration Assays Using a Real-Time Cell Analysis. PLoS ONE. 11(9). e0162553–e0162553. 12 indexed citations
12.
Genua, Marco, Vincenzo Ingangi, Philippe Fonteyne, et al.. (2016). Treatment with a Urokinase Receptor-derived Cyclized Peptide Improves Experimental Colitis by Preventing Monocyte Recruitment and Macrophage Polarization. Inflammatory Bowel Diseases. 22(10). 2390–2401. 18 indexed citations
13.
Ingangi, Vincenzo, Katia Bifulco, Ali Munaim Yousif, et al.. (2016). The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells. Oncotarget. 7(34). 54474–54487. 18 indexed citations
14.
Yousif, Ali Munaim, Michele Minopoli, Katia Bifulco, et al.. (2015). Cyclization of the Urokinase Receptor-Derived Ser-Arg-Ser-Arg-Tyr Peptide Generates a Potent Inhibitor of Trans-Endothelial Migration of Monocytes. PLoS ONE. 10(5). e0126172–e0126172. 25 indexed citations
15.
Bifulco, Katia, Giuseppina Votta, Vincenzo Ingangi, et al.. (2014). Urokinase receptor promotes ovarian cancer cell dissemination through its 84-95 sequence. Oncotarget. 5(12). 4154–4169. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026